Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

Blood blood.2024024300.

https://doi.org/10.1182/blood.2024024300

Published: 2024

Includes: Supplemental data

Journal Articles

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

David O’Connor, Jose Espejo Valle-Inclán, Lucia Conde, Gianna Bloye, Sunniyat Rahman, Joana R. Costa, Jack Bartram, Stuart Adams, Gary Wright, Hillary Elrick, Kerry Wall, Sara Dyer, Christopher Howell, Galina Jigoulina, Javier Herrero, Isidro Cortes-Ciriano, Anthony V. Moorman, Marc R. Mansour

Blood (2024) 143 (10): 933–937.

https://doi.org/10.1182/blood.2023021906

Published: 2024

Includes: Supplemental data

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

Blood (2023) 142 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2023-186025

Published: 2023

Journal Articles

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Blood (2022) 140 (Supplement 1): 1009–1010.

https://doi.org/10.1182/blood-2022-162930

Published: 2022

Journal Articles

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL

Blood (2022) 140 (Supplement 1): 4579–4580.

https://doi.org/10.1182/blood-2022-169114

Published: 2022

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function

Nicola C Maciocia, Amy Burley, Malika Hoekx, Thaneswari Karpanasamy, Lydia Lee, David O'Connor, Marc R. Mansour, Asim Khwaja, Paul M Maciocia, Martin Pule

Blood (2022) 140 (Supplement 1): 4529–4530.

https://doi.org/10.1182/blood-2022-158973

Published: 2022

Journal Articles

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Blood (2022) 140 (Supplement 1): 8987–8988.

https://doi.org/10.1182/blood-2022-162475

Published: 2022

Journal Articles

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy A. Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony V. Moorman, Ajay Vora, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 1720–1721.

https://doi.org/10.1182/blood-2022-165308

Published: 2022

Journal Articles

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

Joana R Costa, David O'Connor, Nurkaiyisah Anuar, Sunniyat Rahman, Nivedita Singh, Zhaodong China, Tanya Rapoz-D'Silva, Yang Li, Kent Fung, Sara Hyseni, Stephen Henderson, George Morrow, Yanping Guo, Javier Herrero, Richard Jenner, Dennis Keppei, A. Thomas Look, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 3046–3047.

https://doi.org/10.1182/blood-2022-166396

Published: 2022

Journal Articles

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Blood (2022) 140 (1): 25–37.

https://doi.org/10.1182/blood.2021013648

Published: 2022

Includes: Supplemental data

Journal Articles

Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia

Paul M Maciocia, Patrycja Wawrzyniecka, Nicola C Maciocia, Amy Burley, David O'Connor, Theresa E. Leon, Tanya Rapoz-D'Silva, Thaneswari Karpanasamy, Martin Pule, Marc R. Mansour

Blood (2021) 138 (Supplement 1): 903.

https://doi.org/10.1182/blood-2021-146565

Published: 2021

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children

David T. Teachey, David O’Connor

Blood (2020) 135 (3): 159–166.

https://doi.org/10.1182/blood.2019001557

Published: 2020

Journal Articles

Trisomy 21 Driven Pro-Inflammatory Signalling in Fetal Bone Marrow May Play a Role in Perturbed B-Lymphopoiesis and Acute Lymphoblastic Leukemia of Down Syndrome

Sorcha Isabella O'Byrne, BSc, Natalina Elliott, PhD, Gemma Buck, BSc, Siobhan Rice, David O'Connor, Jana Oswald, Hannah Fuchs, Ella-Mae Labbett, Nicholas James Fordham, MBBS, BSc, Anindita Roy, MD PhD, Irene Roberts

Blood (2019) 134 (Supplement_1): 1206.

https://doi.org/10.1182/blood-2019-130180

Published: 2019

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Refining genetic stratification in T-ALL

David O’Connor

Blood (2018) 131 (3): 271–272.

https://doi.org/10.1182/blood-2017-10-812933

Published: 2018

Journal Articles

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Maeve A O'Reilly, MB, Dinisha Govender, Ajay Vora, MD, Sujith Samarasinghe, Asim Khwaja, Victoria Grandage, Anupama Rao, Phil Ancliff, Danny Cheng, Ben Carpenter, Stephen Daw, David O'Connor, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 102.

https://doi.org/10.1182/blood.V130.Suppl_1.102.102

Published: 2017

NARROW

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia

Blinatumomab for infant acute lymphoblastic leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children

Trisomy 21 Driven Pro-Inflammatory Signalling in Fetal Bone Marrow May Play a Role in Perturbed B-Lymphopoiesis and Acute Lymphoblastic Leukemia of Down Syndrome

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Refining genetic stratification in T-ALL

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only